PMID- 38254810
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20240128
IS  - 2072-6694 (Print)
IS  - 2072-6694 (Electronic)
IS  - 2072-6694 (Linking)
VI  - 16
IP  - 2
DP  - 2024 Jan 11
TI  - Cell-Free DNA as a Biomarker at Diagnosis and Follow-Up in 256 B and T-Cell 
      Lymphomas.
LID - 10.3390/cancers16020321 [doi]
LID - 321
AB  - BACKGROUND: Cell-free DNA (cfDNA) analysis has become a promising tool for the 
      diagnosis, prognosis, and monitoring of lymphoma cases. Until now, research in 
      this area has mainly focused on aggressive lymphomas, with scanty information 
      from other lymphoma subtypes. METHODS: We selected 256 patients diagnosed with 
      lymphomas, including a large variety of B-cell and T-cell non-Hodgkin and Hodgkin 
      lymphomas, and quantified cfDNA from plasma at the time of diagnosis. We further 
      selected 49 large B-cell lymphomas (LBCL) and analyzed cfDNA levels at diagnosis 
      (pre-therapy) and after therapy. In addition, we performed NGS on cfDNA and 
      tissue in this cohort of LBCL. RESULTS: Lymphoma patients showed a statistically 
      significant higher cfDNA concentration than healthy controls (mean 53.0 ng/mL vs. 
      5.6 ng/mL, p < 0.001). The cfDNA concentration was correlated with lymphoma 
      subtype, lactate dehydrogenase, the International Prognostic Index (IPI) score, 
      Ann Arbor (AA), and B-symptoms. In 49 LBCL cases, the cfDNA concentration 
      decreased after therapy in cases who achieved complete response (CR) and 
      increased in non-responders. The median cfDNA at diagnosis of patients who 
      achieved CR and later relapsed was higher (81.5 ng/mL) compared with levels of 
      those who did not (38.6 ng/mL). A concordance of 84% was observed between NGS 
      results in tumor and cfDNA samples. Higher VAF in cfDNA is correlated with 
      advanced stage and bulky disease. CONCLUSIONS: cfDNA analysis can be easily 
      performed in almost all lymphoma cases. The cfDNA concentration correlated with 
      the characteristics of the aggressiveness of the lymphomas and, in LBCL, with the 
      response achieved after therapy. These results support the utility of cfDNA 
      analysis as a complementary tool in the management of lymphoma patients.
FAU - Diez-Feijoo, Ramon
AU  - Diez-Feijoo R
AUID- ORCID: 0000-0003-3137-3443
AD  - Department of Hematology, Hospital del Mar, 08003 Barcelona, Spain.
AD  - Cancer Research Program, Hospital del Mar Research Institute, 08003 Barcelona, 
      Spain.
FAU - Andrade-Campos, Marcio
AU  - Andrade-Campos M
AD  - Department of Hematology, Hospital del Mar, 08003 Barcelona, Spain.
AD  - Cancer Research Program, Hospital del Mar Research Institute, 08003 Barcelona, 
      Spain.
FAU - Gibert, Joan
AU  - Gibert J
AD  - Cancer Research Program, Hospital del Mar Research Institute, 08003 Barcelona, 
      Spain.
FAU - Sanchez-Gonzalez, Blanca
AU  - Sanchez-Gonzalez B
AD  - Department of Hematology, Hospital del Mar, 08003 Barcelona, Spain.
AD  - Cancer Research Program, Hospital del Mar Research Institute, 08003 Barcelona, 
      Spain.
FAU - Fernandez-Ibarrondo, Lierni
AU  - Fernandez-Ibarrondo L
AUID- ORCID: 0000-0003-2612-0484
AD  - Cancer Research Program, Hospital del Mar Research Institute, 08003 Barcelona, 
      Spain.
FAU - Fernandez-Rodriguez, Concepcion
AU  - Fernandez-Rodriguez C
AUID- ORCID: 0000-0002-5853-0843
AD  - Cancer Research Program, Hospital del Mar Research Institute, 08003 Barcelona, 
      Spain.
AD  - Department of Pathology, Hospital del Mar, Hospital del Mar Research Institute, 
      08003 Barcelona, Spain.
FAU - Garcia-Gisbert, Nieves
AU  - Garcia-Gisbert N
AUID- ORCID: 0000-0002-8185-9786
AD  - Cancer Research Program, Hospital del Mar Research Institute, 08003 Barcelona, 
      Spain.
AD  - Department of Pathology, Hospital del Mar, Hospital del Mar Research Institute, 
      08003 Barcelona, Spain.
FAU - Camacho, Laura
AU  - Camacho L
AD  - Cancer Research Program, Hospital del Mar Research Institute, 08003 Barcelona, 
      Spain.
AD  - Department of Pathology, Hospital del Mar, Hospital del Mar Research Institute, 
      08003 Barcelona, Spain.
FAU - Lafuente, Marta
AU  - Lafuente M
AD  - Cancer Research Program, Hospital del Mar Research Institute, 08003 Barcelona, 
      Spain.
FAU - Vazquez, Ivonne
AU  - Vazquez I
AD  - Department of Pathology, Hospital del Mar, Hospital del Mar Research Institute, 
      08003 Barcelona, Spain.
FAU - Colomo, Luis
AU  - Colomo L
AUID- ORCID: 0000-0001-5236-5085
AD  - Cancer Research Program, Hospital del Mar Research Institute, 08003 Barcelona, 
      Spain.
AD  - Department of Pathology, Hospital del Mar, Hospital del Mar Research Institute, 
      08003 Barcelona, Spain.
FAU - Salar, Antonio
AU  - Salar A
AUID- ORCID: 0000-0002-4652-4825
AD  - Department of Hematology, Hospital del Mar, 08003 Barcelona, Spain.
AD  - Cancer Research Program, Hospital del Mar Research Institute, 08003 Barcelona, 
      Spain.
FAU - Bellosillo, Beatriz
AU  - Bellosillo B
AUID- ORCID: 0000-0002-5335-2726
AD  - Cancer Research Program, Hospital del Mar Research Institute, 08003 Barcelona, 
      Spain.
AD  - Department of Pathology, Hospital del Mar, Hospital del Mar Research Institute, 
      08003 Barcelona, Spain.
LA  - eng
PT  - Journal Article
DEP - 20240111
PL  - Switzerland
TA  - Cancers (Basel)
JT  - Cancers
JID - 101526829
PMC - PMC10813584
OTO - NOTNLM
OT  - cfDNA
OT  - liquid biopsy
OT  - lymphoma
OT  - monitoring
COIS- The authors declare no conflicts of interest.
EDAT- 2024/01/23 06:43
MHDA- 2024/01/23 06:44
PMCR- 2024/01/11
CRDT- 2024/01/23 01:04
PHST- 2023/12/09 00:00 [received]
PHST- 2024/01/04 00:00 [revised]
PHST- 2024/01/05 00:00 [accepted]
PHST- 2024/01/23 06:44 [medline]
PHST- 2024/01/23 06:43 [pubmed]
PHST- 2024/01/23 01:04 [entrez]
PHST- 2024/01/11 00:00 [pmc-release]
AID - cancers16020321 [pii]
AID - cancers-16-00321 [pii]
AID - 10.3390/cancers16020321 [doi]
PST - epublish
SO  - Cancers (Basel). 2024 Jan 11;16(2):321. doi: 10.3390/cancers16020321.